233 related articles for article (PubMed ID: 15985492)
1. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.
Kravariti M; Naka KK; Kalantaridou SN; Kazakos N; Katsouras CS; Makrigiannakis A; Paraskevaidis EA; Chrousos GP; Tsatsoulis A; Michalis LK
J Clin Endocrinol Metab; 2005 Sep; 90(9):5088-95. PubMed ID: 15985492
[TBL] [Abstract][Full Text] [Related]
2. Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome.
Brinkworth GD; Noakes M; Moran LJ; Norman R; Clifton PM
BJOG; 2006 Nov; 113(11):1308-14. PubMed ID: 17059392
[TBL] [Abstract][Full Text] [Related]
3. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors.
Sorensen MB; Franks S; Robertson C; Pennell DJ; Collins P
Clin Endocrinol (Oxf); 2006 Nov; 65(5):655-9. PubMed ID: 17054469
[TBL] [Abstract][Full Text] [Related]
4. Endothelial dysfunction in PCOS: role of obesity and adipose hormones.
Carmina E; Orio F; Palomba S; Longo RA; Cascella T; Colao A; Lombardi G; Rini GB; Lobo RA
Am J Med; 2006 Apr; 119(4):356.e1-6. PubMed ID: 16564785
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
[TBL] [Abstract][Full Text] [Related]
6. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.
Tarkun I; Arslan BC; Cantürk Z; Türemen E; Sahin T; Duman C
J Clin Endocrinol Metab; 2004 Nov; 89(11):5592-6. PubMed ID: 15531516
[TBL] [Abstract][Full Text] [Related]
7. The effects of laparoscopic ovarian drilling on flow mediated dilation in women with PCOS: relationship with insulin resistance and IGF-I.
Shokeir T; El-Kannishy G
Minerva Ginecol; 2014 Apr; 66(2):209-18. PubMed ID: 24848079
[TBL] [Abstract][Full Text] [Related]
8. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition.
Sprung VS; Jones H; Pugh CJ; Aziz NF; Daousi C; Kemp GJ; Green DJ; Cable NT; Cuthbertson DJ
Clin Sci (Lond); 2014 Jan; 126(1):67-74. PubMed ID: 23826984
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function.
Arikan S; Akay H; Bahceci M; Tuzcu A; Gokalp D
Fertil Steril; 2009 Feb; 91(2):450-5. PubMed ID: 18501898
[TBL] [Abstract][Full Text] [Related]
10. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
Pepene CE; Ilie IR; Marian I; Duncea I
Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory and endothelial markers in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Alexandraki K; Piperi C; Protogerou A; Katsikis I; Paterakis T; Lekakis J; Panidis D
Eur J Clin Invest; 2006 Oct; 36(10):691-7. PubMed ID: 16968464
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.
Moran LJ; Hutchison SK; Meyer C; Zoungas S; Teede HJ
Clin Sci (Lond); 2009 May; 116(10):761-70. PubMed ID: 18851710
[TBL] [Abstract][Full Text] [Related]
13. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome.
Mather KJ; Verma S; Corenblum B; Anderson TJ
J Clin Endocrinol Metab; 2000 May; 85(5):1851-6. PubMed ID: 10843164
[TBL] [Abstract][Full Text] [Related]
14. Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study.
Mancini F; Cianciosi A; Reggiani GM; Facchinetti F; Battaglia C; de Aloysio D
Fertil Steril; 2009 Jun; 91(6):2537-44. PubMed ID: 18462732
[TBL] [Abstract][Full Text] [Related]
15. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.
Meyer C; McGrath BP; Teede HJ
J Clin Endocrinol Metab; 2005 Oct; 90(10):5711-6. PubMed ID: 16046590
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovary syndrome and obesity do not affect vascular parameters related to early atherosclerosis in young women without glucose metabolism disturbances, arterial hypertension and severe abnormalities of lipid profile.
Barcellos CR; Lage SH; Rocha MP; Hayashida SA; Baracat EC; Romano A; Brito VN; Marcondes JA
Gynecol Endocrinol; 2013 Apr; 29(4):370-4. PubMed ID: 23327607
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD
J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
[TBL] [Abstract][Full Text] [Related]
18. The relationship between copper, homocysteine and early vascular disease in lean women with polycystic ovary syndrome.
Celik C; Bastu E; Abali R; Alpsoy S; Guzel EC; Aydemir B; Yeh J
Gynecol Endocrinol; 2013 May; 29(5):488-91. PubMed ID: 23480818
[TBL] [Abstract][Full Text] [Related]
19. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome.
Pepene CE
Clin Endocrinol (Oxf); 2012 Jan; 76(1):119-25. PubMed ID: 21740456
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different methods investigating functional and morphological markers of early atherogenesis in obese women with polycystic ovary syndrome.
Jezovnik MK; Jensterle Sever M; Janez A; Pfeifer M; Spirkoska A; Kravos NA; Poredos P
Int Angiol; 2016 Oct; 35(5):446-54. PubMed ID: 26017763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
